Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination

In the dose-escalation phase of a Phase I clinical trial in which six subjects each were vaccinated with PepCan at the 50, 100, 250, and 500 μg per peptide dose, the 50 μg dose showed the best histological regression rate. Ten additional subjects were vaccinated at this dose in the final dose phase....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Immunother
Main Authors: Coleman, Hannah N., Greenfield, William W., Stratton, Shawna L., Vaughn, Rita, Kieber, Alexander, Moerman-Herzog, Andrea M., Spencer, Horace J., Hitt, Wilbur. C., Quick, Charles Matthew, Hutchins, Laura F., Mackintosh, Samuel G., Edmondson, Ricky D., Erickson, Stephen W., Nakagawa, Mayumi
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4841729/
https://ncbi.nlm.nih.gov/pubmed/26980480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1821-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados